More Accurate, Quicker Diagnoses Possible Via New Elsevier Product
Atlanta, June 1, 2006 – Elsevier, the world-leading scientific, technical, and healthcare publisher, launched Path Consult™, a unique, comprehensive online resource that will enable pathologists to make quicker, more accurate diagnoses.
Path Consult is designed to be used in the workplace as a differential diagnosis tool to provide clinical decision support covering every subspecialty area of general pathology. For the first time, pathologists will be able to conduct a side-by-side comparison of up to three diagnoses at a time, significantly reducing the amount of time spent researching the same information offline.
“Path Consult demonstrates Elsevier’s commitment to customers by delivering a truly innovative tool for the end user. Our agile development process is designed to maximize this value in minimum time,” says Jonathan Clark, Executive Vice President, Technology at Elsevier.
Using its established industry leading references from Mosby, Saunders, and Churchill Livingstone, Elsevier developed Path Consult to include more than 10,000 images for more than 500 conditions at launch, and more than 20,000 images for 1200 diagnoses by Fall of 2006.
Path Consult was developed using an agile development process that closely engaged development partners so Elsevier could quickly bring the product to market with the features pathologists really want. The agile process involves a series of product iterations which are adapted based on feedback.
Elsevier worked with leading pathologists to ensure the quality, accuracy, and usability of the online resource. “A plethora of expertly-obtained digital images and succinct textual content combined with the ability to compare similar histopathologic entities at the touch of a button will make the job of any pathologist easier,” says John D. Cochran, MD, a private practice pathologist in Atlanta, Georgia who worked with Elsevier on the development of the product.
Group practices and institutions can sign up for a free trial by visiting www.pathCONSULTDDX.com.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Media Contact:
Janet Blanner
Phone: + 1314 453 4780
Email: j.blanner@elsevier.com
